Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.52 |
| ▸ | HTR1A | P08908 | 4/20 | 0.45 |
| ▸ | HTR7 | P34969 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 2/20 | 0.44 |
| ▸ | FLT4 | P35916 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28510082 | 0.83 | GLO1 (0.51) | KDRDRD2DRD3FLT1FLT4 | |
| SCHEMBL1996584 | 0.77 | L3MBTL1 (0.36) | KDRHTR1AHTR7DRD2DRD3 | |
| SCHEMBL1998981 | 0.76 | DRD2 (0.41) | KDRHTR1AHTR7DRD2DRD3 | |
| SCHEMBL1130169 | 0.76 | DRD2 (0.42) | KDRDRD2DRD3MAPK14 | |
| SCHEMBL28854410 | 0.74 | PTGIR (0.41) | HTR1AHTR7GLO1 | |
| SCHEMBL28954517 | 0.73 | PTGIR (0.43) | HTR1AHTR7 | |
| SCHEMBL591990 | 0.73 | DRD2 (0.47) | KDRHTR1AHTR7DRD2DRD3 | |
| SCHEMBL23531483 | 0.72 | KDM4E (0.38) | HTR1AHTR7 | |
| SCHEMBL2001744 | 0.72 | DRD2 (0.47) | DRD2DRD3 | |
| SCHEMBL23617959 | 0.71 | CYP2C19 (0.45) | KDRDRD2DRD3ADORA2AGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763522-B1 | PYRIDIN-2-ONE COMPOUNDS AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8334289-B2 | Pyridin-2-one compounds and their use as modulators of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110245266-A1 | PYRIDIN-2-ONE COMPOUNDS AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-10-06 | — | — | US | disclosed |
| US-7960386-B2 | 1-(4-{4-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}butyl)-4-methylpyridin-2(1H)-one; treatment of schizophrenia and/or depression | ABBOTT GMBH & CO. KG (DE) | 2011-06-14 | — | — | US | disclosed |
| US-20080261992-A1 | Pyridin-2-One Compounds and Their Use as Modulators of the Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-10-23 | — | — | US | disclosed |
| EP-1763522-A1 | PYRIDIN-2-ONE COMPOUNDS AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-03-21 | — | — | EP | disclosed |
| WO-2005118571-A1 | PYRIDIN-2-ONE COMPOUNDS AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245266-A1 | PYRIDIN-2-ONE COMPOUNDS AND THEIR USE AS MODULATORS OF THE DOPAMINE D3 RECEPTOR | DRD3, DRD2, PTGDR | KDR 620/4885HTR1A 28/4885HTR7 165/4885 |
| US-20080261992-A1 | Pyridin-2-One Compounds and Their Use as Modulators of the Dopamine D3 Receptor | DRD3, DRD2, MTNR1A | KDR 551/4885HTR1A 29/4885HTR7 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.